Date: 2014-05-13
Type of information: Development agreement
Compound: BCL-2 selective inhibitor candidates
Company: Servier (France) Novartis (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: development commercialisation
Action mechanism: Proteins of the BCL-2 family are crucial regulators of apoptosis, the programmed cell death. Deregulations of this protein family play a major role in the aberrant survival of tumor cells. Within this protein family, BCL-2 belongs to the pro-survival members and is often overexpressed in tumor cells.
Disease:
Details: * On May 13, 2014, Servier has announced that they have signed a strategic global collaboration agreement with Novartis to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.The collaboration covers the worldwide co-development of BCL-2 selective inhibitor candidates that are now entering into clinical development.Servier will remain responsible for research activities and will share responsibilities with Novartis to conduct a clinical development program aimed at moving swiftly to a first indication for the benefit of patients. Commercialization rights to products arising from the collaboration will be allocated between the parties on a geographic basis.
Financial terms:
Latest news:
